Guest Blog | ‘Keep off the grass’: the biofuel that could help us achieve net zero

Some grasses are a sustainable energy source that could be a driving force towards achieving net zero carbon emissions, according to new research that demonstrates their resilience to harsh growing environments.

Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss

SHEFFIELD, England, April 20, 2021 /PRNewswire/ -- Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).

CEO Update | Monday 19 April

Today we have published our latest quarterly update which gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from January to April 2021.

WCCT GLOBAL (an Altasciences Company) Clinic Expansion

Laval, Quebec, March 23, 2021 – WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.

Adaptate Biotherapeutics Raises $18 million in Series A2 Funding

• Investment will accelerate the progression of the Company’s lead therapeutic antibody programme towards the clinic and further expand its internal product pipeline • Latest financing takes total funds raised to $34 million

Guest Blog|Incentivising innovation in life sciences requires a fresh debate

New incentives should be explored to encourage innovation in life sciences, especially in areas where the traditional model of incentives might not be working or sufficiently encouraging the development of medicines that society needs.

HotHouse BioEngineering and Leaf Expression Systems Sign Plant-Based Expression License Agreement

NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.

R&D Tax Credits – The three most common areas life sciences companies underclaim

We all know how important R&D tax credits are for the Life Sciences, Pharmaceuticals, and Biotech sectors. Most companies in these industries have been claiming since day one, and yet we often encounter companies who are significantly underclaiming. The average benefit for companies in these industries is just over £110k, but Ayming’s average claim for companies in these industries is currently more than £700k, so why is there such a discrepancy?

CEO Update | Monday 12 April

It was fantastic to see the launch of the Medicines & Diagnostics Manufacturing Transformation Fund which aims to boost economic opportunities, innovation and health resilience by supporting medicines and diagnostics manufacturing investments in the UK.

Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021

Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of MDX-124 - the company’s proprietary therapeutic antibody.